Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Antonio Russo Antonio Galvano |
| Publication date | November 14, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |